# Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection

> **NCT02053350** · PHASE2 · TERMINATED · sponsor: **University of Virginia** · enrollment: 7 (actual)

## Conditions studied

- Clostridium Difficile Infection

## Interventions

- **DRUG:** Alanyl-glutamine

## Key facts

- **NCT ID:** NCT02053350
- **Lead sponsor:** University of Virginia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04
- **Primary completion:** 2017-04-05
- **Final completion:** 2017-04-05
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Funding ended
- **Last updated:** 2022-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02053350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02053350, "Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02053350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*